MX2021001857A - Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama. - Google Patents

Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama.

Info

Publication number
MX2021001857A
MX2021001857A MX2021001857A MX2021001857A MX2021001857A MX 2021001857 A MX2021001857 A MX 2021001857A MX 2021001857 A MX2021001857 A MX 2021001857A MX 2021001857 A MX2021001857 A MX 2021001857A MX 2021001857 A MX2021001857 A MX 2021001857A
Authority
MX
Mexico
Prior art keywords
breast cancer
individual
treatment
methods
tissue sample
Prior art date
Application number
MX2021001857A
Other languages
English (en)
Inventor
Anneleen Daemen
Ciara Metcalfe
Original Assignee
Genentech Inc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc Star filed Critical Genentech Inc Star
Publication of MX2021001857A publication Critical patent/MX2021001857A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Se proporciona en la presente descripción, entre otros, métodos de diagnóstico predictivo, farmacodinámicos y terapéuticos para el tratamiento del cáncer de mama. En modalidades, los métodos y composiciones se basan, al menos en parte, en el descubrimiento de que la puntuación inducida por estradiol (E2) o la puntuación de la actividad de la vía del receptor de estrógeno (ER) determinada a partir de una muestra (por ejemplo, una muestra de tejido, por ejemplo, una muestra de tejido tumoral, por ejemplo, una muestra de tejido tumoral FFPE, una FF, de archivo, una fresca o una congelada) de un individuo se puede usar en métodos para determinar si el individuo que tiene cáncer de mama es probable que responda a un tratamiento que incluye una terapia endocrina, seleccionar una terapia para un individuo que tiene cáncer de mama; tratar a un individuo que tiene cáncer de mama; y monitorear la eficacia terapéutica de una terapia endocrina, así como también kits relacionados.
MX2021001857A 2018-08-17 2019-08-16 Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama. MX2021001857A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862719545P 2018-08-17 2018-08-17
PCT/US2019/046814 WO2020037203A2 (en) 2018-08-17 2019-08-16 Diagnostic and therapeutic methods for the treatment of breast cancer

Publications (1)

Publication Number Publication Date
MX2021001857A true MX2021001857A (es) 2021-10-13

Family

ID=67809706

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001857A MX2021001857A (es) 2018-08-17 2019-08-16 Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama.

Country Status (11)

Country Link
US (2) US11081236B2 (es)
EP (1) EP3837548A2 (es)
JP (1) JP2021533787A (es)
KR (1) KR20210046031A (es)
CN (1) CN113490850A (es)
AU (1) AU2019321588A1 (es)
CA (1) CA3109090A1 (es)
IL (1) IL280707A (es)
MX (1) MX2021001857A (es)
TW (1) TW202022124A (es)
WO (1) WO2020037203A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210046031A (ko) 2018-08-17 2021-04-27 에프. 호프만-라 로슈 아게 유방암 치료를 위한 진단 및 치료 방법들
WO2021178846A1 (en) * 2020-03-06 2021-09-10 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
US11918561B2 (en) 2020-05-12 2024-03-05 Genentech, Inc. Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor
CN111893112A (zh) * 2020-08-12 2020-11-06 上海尤里卡信息科技有限公司 胃癌肿瘤标志物及其应用
CN114105977B (zh) * 2020-08-28 2023-09-01 先声再明医药有限公司 ***受体调节剂化合物及其用途
US20240002950A1 (en) * 2020-11-23 2024-01-04 Sanofi Panel of ER Regulated Genes for Use in Monitoring Endocrine Therapy in Breast Cancer
WO2022140744A1 (en) 2020-12-23 2022-06-30 Recurium Ip Holdings, Llc Estrogen receptor modulators
CN116744920A (zh) * 2021-02-08 2023-09-12 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
EP4294395A1 (en) 2021-02-16 2023-12-27 Genentech, Inc. Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
JP2024506348A (ja) 2021-02-16 2024-02-13 ジェネンテック， インコーポレイテッド Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療
TW202237099A (zh) 2021-02-16 2022-10-01 美商建南德克公司 使用包含ｇｄｃ－９５４５及帕他色替之組合療法治療乳癌
CA3217423A1 (en) 2021-06-16 2022-12-22 Jeffrey M. Schkeryantz Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases
CN117813288A (zh) * 2021-07-15 2024-04-02 西藏海思科制药有限公司 芳氨基衍生物***受体调节剂及其用途
WO2023091550A1 (en) * 2021-11-18 2023-05-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2023198907A1 (en) * 2022-04-15 2023-10-19 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene derivatives, processes for their preparation and therapeutic uses thereof
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2023221122A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
WO2024015506A1 (en) * 2022-07-14 2024-01-18 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
WO2024076633A1 (en) * 2022-10-05 2024-04-11 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
WO2024076626A1 (en) * 2022-10-05 2024-04-11 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
CN1526025A (zh) * 2001-05-16 2004-09-01 ��˹��ŵ�� 作为预后和治疗靶标的乳腺癌中表达的基因
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
BRPI0414553A (pt) * 2003-09-19 2006-11-07 Arcturus Bioscience Inc previsão do resultado de tratamento contra o cáncer de mama
CA2698569A1 (en) * 2007-09-06 2009-09-03 Mark G. Erlander Tumor grading and cancer prognosis
CN102939287B (zh) 2010-06-10 2016-01-27 塞拉根制药公司 ***受体调节剂及其用途
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
SG11201405918XA (en) 2012-03-20 2014-10-30 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
CN104302286A (zh) * 2012-03-27 2015-01-21 英丘伦有限责任公司 用于治疗乳腺癌的curaxin和用于鉴别可能响应的患者的方法
US20150284357A1 (en) 2012-10-24 2015-10-08 Gregory R. Thatcher Compositions and methods for treating estrogen-related medical disorders
CA2928173C (en) 2012-10-24 2021-10-19 The Board Of Trustees Of The University Of Illinois Compositions comprising benzothiophene derivatives and use thereof for treatment of estrogen-related medical disorders
KR102279844B1 (ko) 2012-12-26 2021-07-21 코닌클리케 필립스 엔.브이. 타깃 유전자 발현의 선형 조합(들)을 사용한 세포 시그널링 경로 활성의 평가
US9586952B2 (en) 2013-03-14 2017-03-07 Genentech, Inc. Polycyclic estrogen receptor modulators and uses thereof
EP3044335B1 (en) 2013-09-11 2020-09-09 Bio Theranostics, Inc. Predicting breast cancer recurrence
EP3210144B1 (en) * 2014-10-24 2020-10-21 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
CN108349952A (zh) 2015-11-09 2018-07-31 豪夫迈·罗氏有限公司 四氢萘***受体调节剂及其用途
BR112018015419B1 (pt) 2016-02-05 2024-01-30 Inventisbio Llc Degradantes seletivos de receptor de estrogênio, seus usos, e composição farmacêutica
MX2018009908A (es) 2016-02-15 2018-09-07 Sanofi Sa Derivados de 6,7-dihidro-5h-benzo[7]anuleno como moduladores de receptores de estrogenos.
SG11201808363TA (en) 2016-03-25 2018-10-30 Luoxin Biotechnology Shanghai Co Ltd Substituted-indole compounds as estrogen receptor degrading agent
CN109843882A (zh) 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚***受体调节剂及其用途
JP7018026B2 (ja) 2016-06-16 2022-02-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロアリールエストロゲン受容体モジュレーター及びその使用
WO2018019793A1 (en) 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
US10131663B2 (en) 2016-10-24 2018-11-20 Astrazeneca Ab Chemical compounds
US10774081B2 (en) 2016-10-28 2020-09-15 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Indolo substituted piperidine compound as estrogen receptor down-regulator
AU2017362460B2 (en) 2016-11-17 2021-07-22 Sanofi Novel substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
KR20210046031A (ko) 2018-08-17 2021-04-27 에프. 호프만-라 로슈 아게 유방암 치료를 위한 진단 및 치료 방법들

Also Published As

Publication number Publication date
US20200082944A1 (en) 2020-03-12
US11676731B2 (en) 2023-06-13
US11081236B2 (en) 2021-08-03
CN113490850A (zh) 2021-10-08
IL280707A (en) 2021-03-25
TW202022124A (zh) 2020-06-16
JP2021533787A (ja) 2021-12-09
AU2019321588A1 (en) 2021-03-04
EP3837548A2 (en) 2021-06-23
KR20210046031A (ko) 2021-04-27
WO2020037203A2 (en) 2020-02-20
CA3109090A1 (en) 2020-02-20
US20220044819A1 (en) 2022-02-10
WO2020037203A3 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
MX2021001857A (es) Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama.
Wiegner et al. Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial
MX2018010361A (es) Métodos terapéuticos y de diagnóstico para el cáncer.
MXPA05009044A (es) Metodos para utilizar celulas derivadas de tejido adiposo en el tratamiento de condiciones cardiovasculares.
BR112022020817A2 (pt) Inibidores de kif18a para tratamento de doenças neoplásicas
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
WO2017100663A8 (en) Improved methods for treating her2-positive breast cancer
MX2021003214A (es) Metodos terapeuticos y de diagnostico para el cancer de vejiga.
Johnston et al. The optimal duration of adjuvant endocrine therapy for early stage breast cancer—with what drugs and for how long?
Zhang et al. The use of unilateral or bilateral external oblique myocutaneous flap in the reconstruction of lower abdominal wall or groin defects after malignant tumor resection
MX2021009247A (es) Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1.
Davidson PG 11.01 Endocrine therapy for premenopausal women: type and duration
Koh et al. Comparing a volume based template approach and ultrasound guided freehand approach in multicatheter interstitial accelerated partial breast irradiation
MX2021005189A (es) Uso de tivozanib para tratar sujetos con cancer refractario.
Milecki et al. Hormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients?
Karimkhani et al. Extraosseous extension of multiple myeloma: a cutaneous herald to systemic disease
DK1778834T3 (da) Fremgangsmåder til anvendelse af regenerative celler i behandlingen af renale sygdomme og lidelser
Deantonio et al. Hypofractionated volumetric modulated arc therapy (VMAT) in the treatment of advanced oesophageal cancer
Singhal et al. Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant)
Parks et al. THE ROLE OF THE ANDROGEN RECEPTOR IN PRIMARY BREAST CANCER IN OLDER WOMEN
Dieleman et al. OP003/# 32 Preferences and experiences regarding the use of the self-sampling device in the hrHPV screening for cervical cancer
Bogani et al. OP004/# 35 BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer
Jongen The search for new therapeutic targets in breast cancer: human epidermal growth factor receptor 2 mutations and the androgen receptor
NilujaThiruthaneeswaran et al. Cancer in the Very Elderly and Management
Alsanabani et al. Reliability of Oncoplastic Breast Conserving Surgery for Management of Early Breast Cancer in Yemeni Patients